Σλοβακία -
Σλοβακικά -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
alkeran 5 mg
aspen pharma trading limited - melfalán - 44 - cytostatica
Σλοβακία -
Σλοβακικά -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
dexametazón krka 40 mg tablety
krka, d.d., novo mesto, slovinsko - dexametazón - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
Σλοβακία -
Σλοβακικά -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
dexametazón krka 20 mg tablety
krka, d.d., novo mesto, slovinsko - dexametazón - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
Σλοβακία -
Σλοβακικά -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
dexametazón krka 8 mg tablety
krka, d.d., novo mesto, slovinsko - dexametazón - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
Σλοβακία -
Σλοβακικά -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
dexametazón krka 4 mg tablety
krka, d.d., novo mesto, slovinsko - dexametazón - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
Σλοβακία -
Σλοβακικά -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
dexliq 4 mg/ml perorálny roztok
laboratoires ctrs, francúzsko - dexametazón - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
Σλοβακία -
Σλοβακικά -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
dexamethasone noridem 4 mg/ml injekčný roztok
noridem enterprises ltd., cyprus - dexametazón - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
Ευρωπαϊκή Ένωση -
Σλοβακικά -
EMA (European Medicines Agency)
brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastické činidlá - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
Ευρωπαϊκή Ένωση -
Σλοβακικά -
EMA (European Medicines Agency)
lunsumio
roche registration gmbh - mosunetuzumab - lymfóm, folikulárny - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.